Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma

International Journal of Molecular Sciences

Rajalakshmi Govalan¹  JuDong Yang¹  Vijay Pandyarajan¹ 

[1] Division of Gastroenterology and Hepatology, Samuel Oschin Comprehensive Cancer Institute, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA;

关键词: HBV;    HCC;    liver cancer;    risk factor;    biomarker;    early detection;   

DOI  :  10.3390/ijms22020479

来源: DOAJ

【 摘 要 】

Globally, hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) is one of the major causes of cancer-related mortality. This is, in part, due to delayed diagnosis and limited therapeutic options with more advanced stages of the disease. Given the prognostic importance of early diagnosis, novel methods for early detection are in need. Unlike most other cancer types, tissue is not required to diagnose HCC and is frequently avoided given the inherent risks of liver biopsy, so less invasive methods of obtaining tumor material are currently under investigation. Material shed from tumors into the periphery are being investigated for their potential to both surveil and diagnose patients for HCC. These materials include circulating tumor cells, DNA, RNA, and exosomes, and are collectively termed a “liquid biopsy”. In this review article, we discuss the evolving literature regarding the different risk factors for HCC and the types of emerging novel biomarkers that show promise in the prevention and early diagnosis of HCC within the context of HBV infection.

【 授权许可】

Unknown